<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01798771</url>
  </required_header>
  <id_info>
    <org_study_id>JohannWGUH_IMAGER</org_study_id>
    <secondary_id>206/12</secondary_id>
    <nct_id>NCT01798771</nct_id>
  </id_info>
  <brief_title>Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery</brief_title>
  <acronym>IMAGER</acronym>
  <official_title>Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospitals</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that the rate of radiologically complete resections of
      contrast-enhancing brain tumors following surgeries aided by use of 5-ALA induced
      fluorescence guidance and use of an intraoperative ultra-low field MRI is higher compared to
      surgeries aided by 5-ALA induced fluorescene alone.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Extent of Resection</measure>
    <time_frame>Early postoperative MRI within 72 hrs</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy endpoint is the rate of complete resections according to early postoperative MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volumetric extent of resection</measure>
    <time_frame>Early postoperative MRI within 72hrs</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary endpoint is the volumetric extent of resection as determined by direct comparison of preoperative and early postoperative tumor volumes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS 6</measure>
    <time_frame>6 months following surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary endpoint is the rate of subjects with progression-free survival (PFS) 6 months after tumor resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS 12</measure>
    <time_frame>12 months following surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary endpoint is the rate of subjects with progression-free survival (PFS) 12 months after tumor resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 months/12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient quality of life at 6 and 12 months following surgery is a secondary endpoint</description>
  </secondary_outcome>
  <other_outcome>
    <measure>NIHSS</measure>
    <time_frame>5 days following surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The change of NIHSS (The NIH Stroke Scale) score is an other pre-specified outcome measure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Primary Malignant Neoplasm of Nervous System</condition>
  <condition>Glioma</condition>
  <condition>Glioblastoma</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Interventional arm</intervention_name>
    <description>5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.</description>
    <arm_group_label>Interventional arm</arm_group_label>
    <other_name>5-ALA</other_name>
    <other_name>5-Aminolevulinic acid hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control arm</intervention_name>
    <description>5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.</description>
    <arm_group_label>Control arm</arm_group_label>
    <other_name>5-ALA</other_name>
    <other_name>5-Aminolevulinic acid hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patient (&gt; 18 years) able to give informed consent

          -  primary supratentorial intra-axial brain tumor exhibiting contrast enhancement
             suspected to be malignant glioma

          -  tumor must be deemed completely resectable by neurosurgeon

          -  diagnostic MRI

        Exclusion Criteria:

          -  patient unable or unwilling to give informed consent

          -  infratentorial tumor location

          -  tumor location in or near eloquent areas

          -  multifocal tumor

          -  existance of contraindications to undergo MRI examination

          -  previous surgical treatment for an intraaxial brain tumor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Senft, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Neurosurgery, Johann Wolfgang Goethe University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Senft, MD PhD</last_name>
    <phone>069-6301</phone>
    <phone_ext>5939</phone_ext>
    <email>c.senft@med.uni-frankfurt.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik f√ºr Neurochirurgie Johann Wolfgang Goethe University</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Senft, MD PhD</last_name>
      <phone>069-6301</phone>
      <phone_ext>5939</phone_ext>
      <email>c.senft@med.uni-frankfurt.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S1470204511701966</url>
    <description>Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011 Oct;12(11):997-1003. Epub 2011 Aug 23.</description>
  </link>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 25, 2013</lastchanged_date>
  <firstreceived_date>February 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospitals</investigator_affiliation>
    <investigator_full_name>Dr. Christian Senft</investigator_full_name>
    <investigator_title>PD Dr. med. Christian Senft</investigator_title>
  </responsible_party>
  <keyword>primary brain tumor</keyword>
  <keyword>malignant glioma</keyword>
  <keyword>intraoperative MRI</keyword>
  <keyword>5-ALA</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
